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Enterotoxigenic Bacteroides fragilis (ETBF) causes diarrhea and is implicated in inflammatory bowel dis-
eases and colorectal cancer. The only known ETBF virulence factor is the Bacteroides fragilis toxin (BFT), which
induces E-cadherin cleavage, interleukin-8 secretion, and epithelial cell proliferation. A murine model for
ETBF has not been characterized. Specific pathogen-free (SPF) C57BL/6J or germfree 129S6/SvEv mice were
orally inoculated with wild-type ETBF (WT-ETBF) strains, a nontoxigenic WT strain of B. fragilis (WT-NTBF),
WT-NTBF overexpressing bft (rETBF), or WT-NTBF overexpressing a biologically inactive mutated bft
(rNTBF). In SPF and germfree mice, ETBF caused colitis but was lethal only in germfree mice. Colonic
histopathology demonstrated mucosal thickening with inflammatory cell infiltration, crypt abscesses, and
epithelial cell exfoliation, erosion, and ulceration. SPF mice colonized with rETBF mimicked WT-ETBF,
whereas rNTBF caused no histopathology. Intestinal epithelial E-cadherin was rapidly cleaved in vivo in
WT-ETBF-colonized mice and in vitro in intestinal tissues cultured with purified BFT. ETBF mice colonized
for 16 months exhibited persistent colitis. BFT did not directly induce lymphocyte proliferation, dendritic cell
stimulation, or Toll-like receptor activation. In conclusion, WT-ETBF induced acute then persistent colitis in
SPF mice and rapidly lethal colitis in WT germfree mice. Our data support the hypothesis that chronic
colonization with the human commensal ETBF can induce persistent, subclinical colitis in humans.
In 1984, a molecular subgroup of Bacteroides fragilis, en-
terotoxigenic B. fragilis (ETBF), was identified to cause diarrheal
illnesses in livestock (44) and, in 1992, in humans (40). Subse-
quently, ETBF has been associated with diarrheal disease glo-
bally and, in limited data, active inflammatory bowel diseases
(IBD) (2, 36) and colorectal cancer (50). However, all human
studies of ETBF infection identify a subset of individuals (4
to 30%) asymptomatically colonized with ETBF. Most re-
cently, ETBF was shown to stimulate inflammatory diarrhea in
humans, similar to Shigella spp. (45). The only known virulence
factor for ETBF is a 20-kDa zinc-dependent metalloprotease
called B. fragilis toxin (BFT) or fragilysin (10, 27, 52) that has
three distinct molecular isoforms (bft-1, bft-2, and bft-3) (4, 10,
19). All BFT isoforms exhibit similar biologic activity. Consis-
tent with the clinical observations of ETBF disease, BFT in-
jected into lamb, rabbit, or rat ligated intestinal loops induced
inflammation and fluid accumulation (33). In human colon cell
(38) and colonic epithelial cell (CEC) lines in vitro (3, 32),
BFT increases epithelial barrier permeability associated with
E-cadherin shedding and changes CEC morphology and actin
structure as well as interleukin-8 (IL-8) secretion and CEC
proliferation (57). The lack of murine models for studying
ETBF infections in vivo has impeded understanding of the
molecular mechanisms of ETBF infections (29, 30). Recently,
we described that ETBF colonization in C57BL/6J mice results
in early colitis (by 1 to 2 weeks) and augments dextran sodium
sulfate (DSS)-induced colitis (37). One brief study limited to
histopathology reported that ETBF induces mild colitis in out-
bred germfree mice (31). Pharmacologic doses of BFT are
reported to induce fluid accumulation in ligated murine intes-
tinal loops (17). None of these reports characterized the mu-
rine models or provided insights into ETBF disease pathogen-
esis. Herein, we detail both acute and persistent ETBF colitis
models in C57BL/6J mice and provide evidence that BFT ex-
pression is essential to ETBF disease pathogenesis. Our data
suggest the hypothesis that asymptomatic ETBF colonization
in humans may result in persistent, potentially deleterious,
colitis.
MATERIALS AND METHODS
Bacterial strains. Bacterial strains used in this study are listed in Table 1.
Nontoxigenic wild-type B. fragilis (WT-NTBF) overexpressing bft (rETBF; bft-2)
and WT-NTBF overexpressing a biologically inactive mutated bft (rNTBF; bft-2
H352Y) differ by a single base pair resulting in a single amino acid change in the
BFT-2 catalytic domain; rETBF and rNTBF secrete biologically active and in-
active BFT-2, respectively (8). VPI13784 (bft1) is an isogenic mutant of
VPI13784 containing an in-frame chromosomal deletion of bft-1 (see “Creation
of bft-1 isogenic mutant”). Bacteroides thetaiotaomicron expressing bft-2 was
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constructed as previously described (9). pFD340 is a plasmid vector conferring
clindamycin resistance to transformed Bacteroides strains. All Bacteroides strains
used in this study are naturally resistant to gentamicin. Bacteroides strains were
grown overnight at 37°C under anaerobic conditions (Pack-Anaero; Mitsubishi
Gas Chemical Co., Inc., NY) in brain heart infusion broth supplemented with
hemin, vitamin K1, and cysteine; clindamycin was added into brain heart infusion
broth for transformed strains (46, 54).
Creation of bft-1 isogenic mutant. A bft-1 isogenic mutant was created using
the method of Coyne et al. (5). Briefly, a primer internal to and oriented
upstream of bft (primer 2; XhoI, 5-GGAAGCTGTAACTCGAGTATCAAT
AGA) was used in a PCR analysis with primer 1 (BamHI, 5-TTTACATTGG
ATCCCATGAGATTGGC) located approximately 3 kb upstream of primer 2
(restriction sites are underlined). A second PCR analysis used a primer within bft
oriented downstream (primer 3; XhoI, 5-CATGCGGATGCTCGAGAAGATT
TGAT) with a primer located approximately 3 kb downstream of primer 3
(primer 4; BamHI, 5-CTAAAAGTTGGATCCGTCCCACTGGA) (restriction
sites are underlined). PCRs with primers 1 and 2 and primers 3 and 4 were
performed with high-fidelity DNA polymerase (Life Technologies, Gaithersburg,
MD). The PCR products were digested with BamHI and XhoI cloned by three-
way ligation into the Bacteroides suicide vector pNJR6 at the BamHI site (47).
Ligation of the XhoI sites created an in-frame deletion, removing 90% of the
1,191 bp of bft-1. A plasmid containing the correct orientation of the PCR
products was selected by PCR and introduced into VPI13784 by mobilization
from Escherichia coli using the conjugal helper plasmid pRK231 (51). Single
homologous recombination mutants were selected with clindamycin and, subse-
quently, double homologous recombination mutants as being clindamycin sen-
sitive. VPI13784 bft-1 isogenic mutants were confirmed by PCR analysis, se-
quence analyses, and BFT biologic activity on HT29/C1 cells (28).
Mouse infection. Specific pathogen-free (SPF) 3-week-old male C57BL/6J and
129S6/SvEv mice were purchased from Jackson Laboratories and housed under
SPF conditions. Experimental protocols were approved by the Johns Hopkins
University Animal Care and Use Committee in accordance with the regulations
of the Association for the Assessment and Accreditation of Laboratory Animal
Care International. Based on other mouse enteric colonization models (15), mice
were given water with clindamycin (100 mg/liter) and gentamicin (300 mg/liter)
to promote B. fragilis colonization. Antibiotic water was initiated 7 days prior to
bacterial inoculations and continued for the duration of the experiments. Bac-
teria were washed with filter-sterilized 0.1 N sodium bicarbonate and adjusted to
1  109 CFU/200 l for mouse oral inoculations. Germfree 129S6/SvEv mice and
germfree IL-10 knockout (KO) 129S6/SvEv mice were maintained in the Gno-
tobiotic Core of the Center for Gastrointestinal Biology and Disease at North
Carolina State University (NCSU), College of Veterinary Medicine, and the
National Gnotobiotic Rodent Resource Center, University of North Carolina
(UNC) at Chapel Hill. Gnotobiotic animal use protocols were approved by the
Institutional Animal Care and Use Committees, NCSU and UNC. Germfree
mice were monoassociated with B. fragilis strains between 4 and 10 months of
age.
Fecal analysis. Total fecal bacteria were estimated using a bacterial counting
kit (Molecular Probes). Briefly, a diluted stool sample was stained with a nucleic
acid-specific fluorescent dye, mixed with a known number of microspheres, and
analyzed by flow cytometry. The bacterial density in the sample is calculated from
the ratio of bacterial signals to microsphere signals. B. fragilis colonization
(CFU/g stool) was monitored microbiologically as previously described (37). B.
fragilis was not present in baseline cultures of any mouse (100 analyzed),
indicating that B. fragilis bacteria are not normal colonic flora in C57BL/6J mice.
ETBF and NTBF strains were verified by testing for BFT biologic activity on
HT29/C1 cells or by analysis for the bft gene by PCR as previously described (37).
Histology. Formalin-fixed (10%), paraffin-embedded intestinal tissues were
sectioned (5 m) and stained with hematoxylin and eosin (H&E). Inflammation
during acute infection (up to 1 week) was graded blindly by a board-certified
pathologist as follows: 0, normal; 1, mild increase in inflammatory cells and no
mucosal epithelial changes (no proliferation or loss of crypt structure); 2, mod-
erate increase in inflammatory cells and mild scattered mucosal epithelial pro-
liferation with or without focal loss of crypt architecture; 3, moderate increase in
inflammatory cells, diffuse or nearly diffuse (more than two sites) mucosal epi-
thelial proliferation, and edema with or without focal loss of crypt architecture;
4, severe increase in inflammatory cells and marked consistent proliferation with
extensive loss (more than two sites) of crypt architecture; and 5, complete
destruction of mucosa. Inflammation during chronic infection (4 weeks) was
graded as follows: 0, normal; 1, mild (few infiltrating inflammatory cells and
edema); 2, moderate (focal area affected and mild to moderate infiltration of
inflammatory cells); and 3, marked (focally extensive or diffuse area affected,
with extensive infiltration of inflammatory cells accompanied by either erosion
and/or ulceration). Hyperplasia was graded as follows: 0, normal; 1, slight in-
crease in crypt length and normal CEC; 2, moderate (less than twofold) crypt
length with hyperchromatic CEC and goblet cell loss; and 3, severe (more than
twofold) increase in crypt length with arborized crypts and high mitotic index.
Images were taken using a Nikon E800 camera and rendered using Adobe
Photoshop.
Anti-B. fragilis Western blot analysis. B. fragilis lysates or BFT (purified as
described previously [55]) were electrophoresed under reducing conditions on
precast 4 to 12% gradient sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis gels (NuPage; Invitrogen). Proteins were transferred to a 0.22-m
nitrocellulose membrane (Protran BA83; Whatman), probed overnight with di-
luted murine sera (see Results), and developed with goat anti-mouse immuno-
globulin horseradish peroxidase (ImmunoResearch Laboratories, Bar Harbor,
ME) and SuperSignal West Pico chemiluminescent substrate (Pierce). B. fragilis
lysates were prepared by mechanically disrupting the bacterial cells with glass
beads (Mini-Beadbeater 3110BX; BioSpec Products, Bartlesville, OK) for 3 min
at 5,000 rpm, clarified by centrifugation, and protein quantified using the bicin-
choninic acid assay (Pierce Biotechnology, Rockford, IL).
In vitro and ex vivo E-cadherin cleavage. Mouse intestines were excised,
opened longitudinally, washed extensively with cold phosphate-buffered saline to
remove all fecal material, and laid flat onto a petri dish to obtain full-thickness
punch biopsies (3 mm in diameter). Biopsies were incubated with or without
purified BFT (5 nM) in serum-free Dulbecco’s modified Eagle’s medium for 15
min and then lysed on ice for 15 min in radioimmunoprecipitation assay lysis
buffer (Sigma). Clarified intestinal lysates and culture supernatants were stored
at 20°C until analyzed by Western blot analysis using monoclonal antibodies
against E-cadherin (N-terminal specific; clone ECCD-2; Invitrogen), transferrin
receptor (clone H68.4; Invitrogen), pan-cytokeratin (clone C-11; Invitrogen), or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; clone 6C5; Calbiochem).
Ex vivo experiments to detect E-cadherin cleavage were also performed with
ceca from mice infected with B. fragilis strains as described above (“Mouse
TABLE 1. Bacterial strains used in this study
Designation BFT isoformand activity Strain
a Relevant characteristics Source orreference
WT-ETBF (bft-2) BFT-2 B. fragilis 86-5443-2-2 Piglet isolate 29
WT-NTBF None B. fragilis NCTC 9343 Transformed with pFD340; human isolate 9
rETBF (bft-2) BFT-2 B. fragilis NCTC 9343 Transformed with bft2::pFD340 9
rNTBF (bft-2 H352Y) Noneb B. fragilis NCTC 9343 Transformed with inactive bft2 H352Y::pFD340 8
WT-ETBF (bft-1) BFT-1 B. fragilis VPI 13784c Transformed with pFD340; lamb isolate This paper
WT-ETBF (bft1) Noneb B. fragilis VPI 13784c Transformed with pFD340; in-frame chromosomal
deletion of bft-1
This paper
WT-ETBF (bft-3) BFT-3 B. fragilis Korea 570 Human blood isolate 4
BT4001 None B. thetaiotaomicron 4001d Transformed with pFD340 This paper
BT4001 (bft-2) BFT-2 B. thetaiotaomicron 4001d Transformed with bft-2::pFD340 This paper
a All strains used in this study are resistant to clindamycin either naturally or by introduction of pFD340.
b Biologically inactive BFT or bft deletion mutant.
c B. fragilis VPI 13784 was originally from Tracy Wilkins (51).
d Bacteroides thetaiotaomicron strain 4001 was originally from Nadja Shoemaker (11). pFD340::bft-2 was transformed into B. thetaiotaomicron as described previously (9).
VOL. 77, 2009 INDUCTION OF PERSISTENT COLITIS BY B. FRAGILIS 1709
infection”) for 12, 18, and 24 h. Ceca were evaluated by histopathology and
processed for Western blot analysis in parallel as described above.
TLR activation. HEK 293 stable transfectants expressing human Toll-like
receptor 2 (TLR-2), -3, -4, -7, or -9 were stimulated with either purified BFT (5
nM), TLR ligands (positive controls), or unstimulated (negative controls) for
24 h and conditioned medium frozen at 80°C until assayed for IL-8 secretion
by enzyme-linked immunosorbent assay (R&D Systems) (14). HEK 293 cell TLR
transfectants secrete IL-8 upon stimulation with TLR ligands. HEK 293 cells
naturally express TLR-5 (23).
Splenocyte proliferation assay. Splenocytes from C57BL/6J mice were pre-
pared by gentle sieving on a nylon mesh (100 m; BD Falcon) followed by lysis
of red blood cells (ACK lysing buffer; Biosource). The cells were washed exten-
sively, resuspended in 2% fetal bovine serum RPMI 1640 medium at a final
concentration of 1  106 cells/ml and divided into aliquots (100 l per well) into
flat-bottomed 96-well plates in triplicate. Purified BFT (5 nM [100 ng/ml final]),
anti-mouse CD3ε (clone 145-2C11, 100 ng/ml), lipopolysaccharide (100 ng/ml;
Alexis, San Diego, CA), or culture medium alone was added to the cells, followed
by 48-h culture. Cells were pulsed with 1 Ci of [3H]thymidine for the final 12 h
of the culture period. After lysis, the [3H]thymidine incorporated into the spleno-
cytes was counted with a liquid scintillation counter.
BMDCs. Bone marrow-derived dendritic cells (BMDCs) from C57BL/6J mice
were generated as reported by Lu et al. (24). Briefly, bone marrow was collected
from tibias and femurs by flushing with RPMI 1640 culture medium. After lysing
red blood cells, cells were cultured with recombinant granulocyte-macrophage
colony-stimulating factor (1,000 U/ml; R&D Systems) to induce dendritic cell
differentiation. After 6 days, BMDCs were incubated with purified BFT (5 nM
[100 ng/ml final]), lipopolysaccharide (100 ng/ml), or culture medium alone (2%
fetal bovine serum RPMI 1640 medium). After 20 h, cells were harvested for flow
cytometric analysis (anti-CD11c, anti-MHC-II, anti-CD86, and anti-CD40; all
from BD Biosciences), and conditioned medium was collected for cytokine
secretion analysis (BD cytometric bead array, catalogue no. 552364; detects
murine IL-6, IL-10, monocyte chemoattractant protein 1, gamma interferon,
tumor necrosis factor alpha, and IL-12 p70).
Data analysis. For statistical analysis of inflammation and hyperplasia scores,
the Mann-Whitney U test was used to compare between-group distributions for
unpaired data. All other data are presented as means 	 standard errors of the
means. Comparison of means was done by unpaired Student’s t test. A P value
of 0.05 was considered statistically significant.
RESULTS
Acute ETBF infection (1 to 2 weeks). (i) Clinical character-
istics. After 1 week of antibiotic pretreatment, stool bacterial
counts analyzed by fluorescence-activated cell sorting dropped
by 10- to 100-fold to 1010 to 1011 bacterial cells/g stool.
Acute infection experiments were initially performed using
WT-ETBF (bft-2), WT-NTBF, and rETBF (bft-2) (Table 1). At
24 h postinoculation, all three B. fragilis strains were recovered
in high numbers from the stool (109 to 1010 CFU/g stool),
and this level of bacterial colonization density persisted for the
duration of the experiment (data not shown). Therefore, a high
level of colonization of mice with B. fragilis strains is rapid and
stable in our mouse model.
WT-ETBF (bft-2)-colonized mice were usually lethargic at
2 to 3 days postinoculation, with ruffled fur and a hunched
posture with transient weight loss (Fig. 1a) and occasional
rectal bleeding. A small percentage (5.4%; 3 of 55 mice) of
WT-ETBF (bft-2)-colonized mice died at 2 to 3 days postcolo-
nization (Fig. 1b). Mortality did not appear to be due to bac-
teremia as aerobic and anaerobic blood cultures of WT-ETBF
(bft-2)-infected mice (n 
 5) at 2 days postinfection were
negative for B. fragilis or other bacterial species. The stool of
WT-ETBF (bft-2)-colonized mice ranged from moist, but
formed, to transient diarrhea, usually at 1 to 3 days postcolo-
nization. Thus, the deaths may be related to fluid or electrolyte
imbalances secondary to enteric disease. All surviving WT-
ETBF (bft-2)-colonized mice were healthy in appearance and
activity by approximately day 4 to 5 in association with the
onset of weight gain (Fig. 1a). WT-NTBF-colonized and mock-
infected mice appeared healthy at all times and, except for the
first day in NTBF-colonized mice, continuously gained weight
(Fig. 1a).
(ii) Gross morphology and histology. By 7 days postcoloni-
zation, the ceca of WT-ETBF (bft-2)-colonized mice appeared
smaller and, in some mice, lacked cecal contents or contained
blood clots compared to those of WT-NTBF-colonized mice or
mock-infected mice (Fig. 1c and inset). Consistent with the
observed decrease in the size of ceca in WT-ETBF (bft-2)-
colonized mice, cecal weights were significantly less in WT-
ETBF (bft-2)-colonized mice compared to those in mock-in-
fected and WT-NTBF-colonized mice. The decreased sizes of
ceca in WT-ETBF (bft-2)-colonized mice occurred within 2
days of oral colonization (data not shown). Decreases in the
sizes of ceca with marked inflammation have also been noted
in Citrobacter rodentium (25) and Salmonella enterica serovar
Typhimurium (1) murine models and likely represent a re-
sponse to cecal injury. Colon length decreased substantially in
DSS-treated mice, and this correlates with the extent of in-
flammation (34). The average colon length of WT-ETBF (bft-
2)-colonized mice was similar to that of WT-NTBF-colonized
mice or mock-infected mice (data not shown). The only gross
difference between the colons of WT-ETBF (bft-2)-colonized
mice and those of WT-NTBF-colonized mice was that the
proximal colons of WT-ETBF (bft-2)-colonized mice con-
tained semisolid stool, whereas the WT-NTBF-colonized mice
had well-formed stool. Although there is some variability be-
tween individual ETBF-colonized mice, splenomegaly (P 
0.0001) as well as enlarged mesenteric lymph nodes (data not
shown) were noted in most WT-ETBF (bft-2)-colonized mice
(Fig. 1d and inset).
Histopathology of the colons of WT-ETBF (bft-2)-colonized
mice revealed edema and inflammatory cell infiltration with
rounding and detachment of enterocytes by day 2 postinfection
(Fig. 2a and c). By day 7 postinfection, the WT-ETBF (bft-2)-
colonized mice had mucosal thickening with mucosal and sub-
mucosal edema, crypt hyperplasia, and elongation and exten-
sive neutrophilic infiltration into both the mucosa and
submucosa with epithelial cell destruction resulting in erosions
and ulceration (Fig. 2b and c). Scattered crypt abscesses were
observed in the colons. Inflammation and hyperplasia were
usually more severe in the proximal than distal colons in WT-
ETBF (bft-2)-colonized mice. The jejunums and ileums were
normal. WT-NTBF-colonized mice and mock-infected mice
exhibited no colonic histopathology abnormalities.
Antibody responses to B. fragilis and BFT. Splenomegaly
and enlarged mesenteric lymph nodes in WT-ETBF (bft-2)-
colonized mice suggested activation of a systemic immune re-
sponse. Thus, we examined sera for anti-Bacteroides antibodies
at day 7 postcolonization. Pooled sera from three WT-ETBF
(bft-2)-colonized mice reacted specifically to diffuse high-mo-
lecular-weight bands in WT-ETBF (bft-2), but not WT-NTBF,
lysates; pooled sera from WT-NTBF-colonized and mock-in-
fected mice did not react to either WT-ETBF (bft-2) or WT-
NTBF lysates (Fig. 3). However, Western blots exposed for a
longer amount of time (1 h) revealed that sera from WT-
NTBF-colonized mice reacted specifically to WT-NTBF lysates
(Fig. 3). These results suggest that WT-ETBF (bft-2)- and
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WT-NTBF-colonized mice both develop B. fragilis strain-spe-
cific antibodies. No BFT-specific antibodies were detected in
mice colonized with WT-ETBF (bft-2) for up to 8 months (data
not shown).
BFT and ETBF induce E-cadherin cleavage in mouse intes-
tine. BFT induces E-cadherin cleavage with shedding of the
80-kDa extracellular E-cadherin domain from the surface of
human CEC lines in vitro (56, 59). It is unknown whether BFT
induces cleavage of E-cadherin of other species or if ETBF
induces E-cadherin cleavage in vivo. Thus, we analyzed punch
biopsies of small intestines, ceca, and colons from naïve mice
incubated with purified BFT (5 nM) in vitro by Western blot
analysis for E-cadherin cleavage. Both a decrease in the inten-
sity of full-length membrane-bound E-cadherin (120 kDa)
and accumulation of the “shed” extracellular fragment of E-
cadherin (80 kDa) into the culture supernatants were ob-
served in all tissues examined (Fig. 4a). BFT-induced cleavage
of mouse E-cadherin is likely specific since cleavage of another
transmembrane protein, the transferrin receptor, was not ob-
served.
To determine if E-cadherin cleavage occurs in WT-ETBF
(bft-2)-colonized mice, cecal tissues were examined in mice at
12, 18, and 24 h postinfection. At 12 h postinfection, cecal
lysates from WT-ETBF (bft-2)-colonized mice showed no dif-
ference in full-length membrane-bound E-cadherin compared
to WT-NTBF-colonized and mock-infected mice (Fig. 4b). In
contrast, progressive loss of the E-cadherin band occurred at
18 h and 24 h in WT-ETBF (bft-2)-colonized mice compared to
that in WT-NTBF-colonized mice. Loss of full-length E-cad-
herin correlated with the onset of colitis (Fig. 4c). Pan-cytok-
eratin (a CEC marker) and transferrin receptor levels (data
not shown) were unaffected, suggesting that CEC loading was
uniform and that the observed E-cadherin cleavage is not due
to nonspecific, inflammation-associated degradation of trans-
membrane proteins.
Catalytically active BFT expressed by Bacteroides species is
necessary and sufficient to induce colitis. To date, BFT is the
only known virulence factor specific to ETBF strains. To de-
termine the contribution of biologically active BFT to ETBF
colitis, mice were colonized with rETBF (bft-2) and rNTBF
FIG. 1. Clinicopathologic analysis of C57BL/6 mice inoculated with B. fragilis (1  109 CFU) for 7 days. (a) Weight change. The daily body
weight of individual mice was normalized to the starting body weight. Shown are pooled data from three independent experiments, with 4 to 15
mice per experiment. The baseline weight (in grams) of individual mice was similar between the three mouse groups as follows: mock-infected mice
(Mock), 14.42 	 0.35 (standard error of the mean); WT-NTBF-infected mice, 14.62 	 0.43; and WT-ETBF (bft-2)-infected mice, 14.47 	 0.42.
*, a P value of 0.001 for WT-ETBF (bft-2)-infected mice compared with either WT-NTBF- or mock-infected mice, except for day 1 which is
significant (P  0.005) only compared with mock-infected mice; #, a P value of 0.01 for WT-NTBF-infected mice compared with mock-infected
mice. (b) Mortality of WT-ETBF (bft-2)-infected (n 
 55), WT-NTBF-infected (n 
 44), or mock-infected (n 
 35) mice. Shown are pooled data
from seven independent experiments. (c) Cecal weight and gross morphology (a total of 5 to 7 mice) (inset). (d) Spleen weight and gross
morphology (a total of 5 to 7 mice) (inset). Bars, median weight. NS, statistically not significant.
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(bft-2 H352Y) that differ by one amino acid, resulting in ex-
pression of biologically active or inactive BFT-2, respectively
(Table 1; see Materials and Methods). rETBF (bft-2)-colo-
nized mice were similar to WT-ETBF (bft-2)-colonized mice,
developing lethargy, ruffled fur, and, in several mice, rectal
bleeding. Mortality was usually similar to that of mice infected
with WT-ETBF (bft-2), but it did reach 90% by 7 days in two
of five experiments (5 to 7 mice per group; data not shown).
The time course and extent of colon inflammation as well as
E-cadherin cleavage were similar in WT-ETBF (bft-2)- and
FIG. 2. ETBF induces acute colitis. H&E-stained tissue sections of mock-, WT-NTBF-, WT-ETBF (bft-2)-, and rETBF (bft-2)-infected mice for 2 days (a)
and 7 days (b). Boxed areas were digitally magnified (100). Bars, 100 m. (c) Histologic inflammation scores of large bowels of infected mice at day 1, day 2,
day 3, and day 7. Results of mock-infected mice were identical to those of WT-NTBF-infected mice (data not shown). Asterisks denote a lack of inflammation
(an inflammation score of 0.2). (d) H&E-stained cecal tissue sections from BT4001- and BT4001 (bft-2)-infected mice.
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rETBF (bft-2)-colonized mice (Fig. 2 and 4). rNTBF (bft-2
H352Y)-colonized mice exhibited no gross or histopathologic
colon abnormalities. BFT in stool from both rETBF (bft-2)-
and rNTBF (bft-2 H352Y)-infected mice was detected by
Western blot analysis, demonstrating in vivo expression of both
WT-BFT and mutated BFT, respectively (data not shown). To
determine if bft-2 expressed by a non-Bacteroides fragilis strain
can induce inflammation, we infected mice with a Bacteroides
thetaiotaomicron strain overexpressing bft-2 (Table 1) (Fig. 2d)
and found that colitis ensued (Table 2). In addition, mice
colonized with a bft-1-expressing strain of WT-ETBF (Table 1)
exhibited colitis, whereas no colitis occurred in mice colonized
with an isogenic mutant strain, WT-ETBF (bft-1) (Table 1),
in which an in-frame chromosomal deletion of bft-1 was con-
structed. Finally, a bft-3-expressing WT-ETBF strain (Table 1)
also induced colitis (Table 2). These results show that WT-
ETBF strains expressing each of the three bft isoforms induce
colon inflammation in WT C57BL/6 mice and, furthermore,
that biologically active BFT is necessary and sufficient to in-
duce colitis.
Persistent ETBF infection (1 month to 16 months). WT
C57BL/6 mice colonized for a period spanning 1 to 16
months demonstrated consistently high colonization (range,
109 to 1010 CFU/g stool) with the B. fragilis strains [WT-
ETBF (bft-2), WT-NTBF, rETBF (bft-2), and rNTBF (bft-2
H352Y)]. Mice persistently colonized with WT-ETBF (bft-2)
and rETBF (bft-2) appeared healthy, similar to WT-NTBF-,
rNTBF (bft-2 H352Y)-, or mock-infected mice. At 3 months,
WT-ETBF (bft-2)-colonized mice were similar in weight to
WT-NTBF-colonized mice and mock-infected mice [mock in-
fected, 30 	 2 g; WT-NTBF infected, 33 	 2 g; WT-ETBF
(bft-2) infected, 30 	 2 g; the P value was not statistically
significant; 5 to 7 mice per group]. However, some of the
WT-ETBF (bft-2)- and rETBF (bft-2)-infected mice still exhib-
ited visible blood in the cecal lumens as well as colon inflam-
mation and hyperplasia at 1, 3, 8, and 16 months (Tables 3
and 4). To verify hyperplasia, the nuclear protein Ki67 was
used to detect proliferating cells. Colons from WT-ETBF (bft-
2)-colonized mice exhibited an increased percentage of Ki67-
positive crypt cells (46.9% 	 2.1%) compared to those from
WT-NTBF-colonized mice (36.1% 	 2.5%) or mock-infected
controls (31.5% 	 2.1%) [a P value of 0.004 for WT-ETBF
(bft-2)- versus WT-NTBF-infected mice or controls at 1
month]. BFT stimulates -catenin nuclear signaling in vitro
with induction of c-Myc expression (57), a protein critical to
cell growth. To examine if ETBF hyperplasia may involve c-
Myc-regulated mechanisms, expression of cyclin D1, a cell
growth gene regulated by c-Myc, was examined in mice colo-
nized with WT-ETBF (bft-2) for 1 month. Enhanced cyclin D1
expression was detected in WT-ETBF (bft-2)-colonized mice
compared to that in control mice (Fig. 5). Mice persistently
infected with ETBF for 8 months and 16 months also showed
epithelial hyperplasia. These results suggest that ETBF and
NTBF strains can persistently colonize WT C57BL/6 mice but
only ETBF strains induce chronic colon inflammation and hy-
perplasia.
ETBF infection of germfree mice. Thus far, our results dem-
onstrate that infection with various ETBF strains induced co-
litis in conventional WT mice. However, it is possible that
ETBF acts cooperatively with other microbial flora to induce
colitis and that ETBF alone does not induce inflammation.
Thus, to determine if ETBF alone induces colitis, 129S6/SvEv
germfree mice were infected with either WT-ETBF (bft-2) or
WT-NTBF. Unexpectedly, 100% of germfree mice inoculated
with WT-ETBF (bft-2) (n 
 6) died abruptly by day 3 postin-
oculation. Histopathology showed severe colitis in all WT-
ETBF (bft-2)-colonized mice (Fig. 6). Histopathology of the
lungs, livers, and spleens was unremarkable (data not shown).
Germfree mice inoculated with WT-NTBF (n 
 10) did not
develop intestinal inflammation even when persistently colo-
nized for up to 13 weeks. In a parallel experiment, germfree
IL-10 KO 129S6/SvEv mice infected with WT-ETBF (bft-2)
also developed fatal, rapid onset colitis, whereas germfree
IL-10 KO 129S6/SvEv mice infected with WT-NTBF remained
healthy with normal colonic histology after 13 weeks (data not
shown).
We next determined whether colonization of germfree mice
with rETBF (bft-2) was sufficient to induce colitis as we ob-
served in conventional mice. In contrast to the rapid onset of
lethal colitis noted with WT-ETBF (bft-2)-colonized germfree
FIG. 3. Western blot analysis of mouse serum against B. fragilis (B.f.) lysates. Shown are pooled sera (1:500 dilution) from mock-infected
(Mock), WT-NTBF-infected, or WT-ETBF (bft-2)-infected mice evaluated on B. fragilis lysates. Films were exposed for 10 s and 1 h.
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129S6/SvEv mice, all mice monoassociated with rETBF (bft-2)
(n 
 9) or rNTBF (bft-2 H352Y) (n 
 10) for 3 days appeared
healthy and exhibited a high level of colonization (1010
CFU/g stool). Histopathology at 3 days postinoculation re-
vealed marked cecal inflammation with ulcerations in mice
infected with rETBF (bft-2) but not rNTBF (bft-2 H352Y)
(Fig. 6). These results indicate that ETBF alone induces colitis
and confirm that BFT expression alone is sufficient to induce
colitis. However, rETBF (bft-2) did not recapitulate the com-
plete phenotype of WT-ETBF (bft-2) in germfree mice, sug-
gesting that other virulence factors of WT-ETBF (bft-2) con-
tribute to rapidly progressive colitis in these mice. The sudden
death observed in germfree mice after WT-ETBF (bft-2) inoc-
ulation is not due to the 129S6/SvEv mouse strain background,
as SPF 129S6/SvEv mice infected with WT-ETBF (bft-2) ex-
hibited colonic inflammation with little lethality (5%) similar
to C57BL/6 mice (data not shown).
Purified BFT does not stimulate lymphocytes, TLRs, or den-
dritic cells. The rapid, lethal colitis observed in WT-ETBF
(bft-2)-infected germfree 129S6/SvEv mice prompted us to test
if BFT was acting as a bacterial superantigen. Bacterial super-
antigens such as staphylococcal enterotoxin B are low-molec-
ular-weight proteins that directly ligate major histocompatibil-
ity complex class II (MHC-II) molecules and the variable chain
of the T-cell receptor, triggering vigorous T-cell proliferation,
FIG. 4. ETBF induces E-cadherin cleavage in vitro and ex vivo. (a) Uninfected mouse small intestine (Si), cecum (Ce), and mid-colon (Co) tissues
cultured with () or without () purified BFT (5 nM) for 15 min and probed for E-cadherin (N terminus specific) in the lysate and the supernatant.
Results are representative of three independent experiments. Pan-cytokeratin was used as a CEC loading control, and GAPDH was used as a total protein
loading control. (b) Mice were infected for 12, 18, and 24 h, and the ceca were cut lengthwise into two pieces. (c) One piece was used for Western blot analysis
and the second half was used for H&E sections. Results are representative of two independent experiments (a total of three mice per experiment).







rETBF (bft-2) 2 3.0 (1.5–3.5)* 6
rNTBF (bft-2 H352Y) 2 0.0 (0) 3
WT-ETBF (bft-1) 2 2.5 (2–3)** 6
WT-ETBF (bft-1) 2 0.0 (0–0.5) 6
WT-ETBF (bft-3) 1–2 1.5 (1–2.5) 6
BT4001 1 0.0 (0–1) 4
BT4001 (bft-2) 1 3.5 (2.5–3.5)*** 6
a The Mann-Whitney U test was used to compare between-group distributions
for unpaired data. *, a P value of 0.05 compared with rNTBF-infected mice; **,
a P value of 0.05 compared with WT-ETBF (bft-1)-infected mice; ***, a P
value of 0.05 compared with BT4001 (bft-1)-infected mice.
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cytokine production, and rapidly progressive, potentially fatal
illnesses (e.g., staphylococcal toxic shock syndrome). Com-
pared to anti-CD3-treated mouse splenocytes (positive con-
trol), BFT (5 nM) did not induce splenocyte proliferation
([3H]thymidine uptake, 496 	 19 cpm BFT versus 33,333 	
3,528 cpm T-cell receptor antibodies; a total of three experi-
ments), indicating that BFT is not a superantigen. Due to the
rapid onset of colonic disease with a marked infiltration of
neutrophils, we determined if BFT activates TLRs, mediators
of innate immune responses. HEK 293 cells do not bind to
BFT and exhibit no biologic responses to BFT (data not
shown). HEK 293 cells overexpressing TLR-2, -3, -4, -7, or -9
were tested for reconstitution of BFT biologic activity and
secretion of IL-8. Compared to the positive control TLR li-
gands for each receptor, BFT did not stimulate IL-8 secretion
from any TLR-expressing HEK 293 cell lines, suggesting that
BFT does not directly activate the TLRs tested (data not
shown). Lastly, we determined whether purified BFT can ac-
tivate BMDCs in vitro. BMDCs from C57BL/6J mice cultured
with purified BFT (5 nM) were not activated based on fluo-
rescence-activated cell sorting analysis of BMDC activation
markers (i.e., MHC-II, CD80, and CD86) and based on secre-
tion of inflammatory cytokines (data not shown). These results
suggest that BFT does not directly stimulate lymphocytes and
dendritic cells nor does it activate TLR pathways in vitro.
DISCUSSION
Using a murine model, we demonstrate for the first time that
ETBF, often a human commensal in clinical studies conducted
to date, induces not only acute, symptomatic colitis but persis-
tent subclinical colonic inflammation and hyperplasia. These
observations reinforce and extend results from our prior report
indicating that ETBF induces murine colitis (37). This new
model of colonic inflammation differs substantially from the
majority of other reported inbred murine IBD models (30) in
which intestinal inflammation develops in mice with host im-
munoregulatory defects (e.g., IL-2- or IL-10-deficient mice)
(22, 41). In contrast, C57BL/6 mice are viewed as colitis resis-
tant (7). A unique aspect of the ETBF C57BL/6 murine colitis
model is the ability of both ETBF and NTBF strains to per-
sistently colonize the murine colon, akin to what is observed
for B. fragilis in humans and distinct, for example, from
Citrobacter rodentium murine colitis in which the mice clear C.
rodentium in 4 to 6 weeks (25).
BFT is the only known virulence factor described specifically
for ETBF strains. Our experiments demonstrate that all three
isoforms of BFT stimulate colonic inflammation and that bio-
logically active BFT expression is necessary and sufficient to
induce murine colitis. This conclusion is supported by our
studies of a WT-NTBF strain engineered to express either
biologically active or inactive BFT (i.e., rETBF or rNTBF,
respectively); demonstration of colitis induced by a WT-ETBF
(bft-1) strain but not its isogenic deletion mutant and by the
induction of colitis by the nonpathogenic Bacteroides thetaio-
taomicron transformed with bft-2. Reported data suggest that
B. thetaiotaomicron is a lumen-residing commensal species,
whereas B. fragilis associates with the colonic mucosa, possibly
due to its ability to change capsular antigenicity (6, 21). Our
observations that the BFT-expressing B. thetaiotaomicron in-
duces colitis suggest that close delivery of BFT to the mucosa
by B. fragilis may not be required for the induction of inflam-
mation. Alternatively, expression of BFT by B. thetaiotaomi-
cron and/or B. thetaiotaomicron colonization in a murine model
treated with antibiotics enhances B. thetaiotaomicron mucosal
TABLE 3. Cecum and colon inflammation scores of mice persistently infected with different B. fragilis strainsa
Strain or type of
infection
Median (range) inflammation score, no. of mice at:
1 mo 3 mo 8 mo 16 mo
Cecum Colon Cecum Colon Cecum Colon Cecum Colon
Mock 0.0 (0–1), 6 0.0 (0–0.5), 3 ND ND 0.0 (0), 3 0.0 (0), 3 0.0 (0–1), 4 0.0 (0), 4
WT-ETBF (bft-2) 2.25 (2–3), 8* 1.0 (0.5–1.5), 5* 2.0 (2–3), 5* 2.0 (1–2), 5* 2.0 (1–2), 3* 1.0 (0–1), 3 2.5 (2–3), 6* 2.5 (2–3), 6*
WT-NTBF 0.0 (0–1), 7 0.0 (0), 4 0.5 (0–1), 4 0.0 (0), 4 0.0 (0), 3 0.0 (0), 3 0.0 (0–1), 8 0.0 (0–1), 8
rETBF (bft-2) 3.0 (3), 3** ND ND ND ND ND 1.0 (1–3), 9** 1.0 (0–3), 9**
rNTBF (bft-2 H352Y) 0.0 (0–1), 3 ND ND ND ND ND ND ND
a The Mann-Whitney U test was used to compare between-group distributions for unpaired data. , a P value of 0.05 compared with mock-infected and
WT-NTBF-infected mice; , a P value of 0.05 compared with rNTBF- and WT-NTBF-infected mice. ND, not determined.
TABLE 4. Cecum and colon hyperplasia scores of mice persistently infected with different B. fragilis strainsa
Strain or type of
infection
Median (range) hyperplasia score, no. of mice at:
1 mo 3 mo 8 mo 16 mo
Cecum Colon Cecum Colon Cecum Colon Cecum Colon
Mock 0.0 (0), 6 0.5 (0–0.5), 3 ND ND 0.0 (0), 3 0.0 (0), 3 0.0 (0–1), 4 0.0 (0–1), 4
WT-ETBF (bft-2) 2.0 (1.5–3), 8* 1.5 (1–2), 5* 3.0 (2–3), 5* 2.0 (2–3), 5* 3.0 (1–3), 3* 1.0 (0–2), 3 3.0 (2–3), 6* 2.0 (2–3), 6*
WT-NTBF 0.0 (0–1), 7 0.25 (0–0.5), 4 0.5 (0–1), 4 0.0 (0–1), 4 0.0 (0), 3 0.0 (0), 3 0.0 (0–2), 8 0.0 (0–1), 8
rETBF (bft-2) 2.0 (2), 3** ND ND ND ND ND 2.0 (1–3), 9** 2.0 (1–3), 9**
rNTBF (bft-2 H352Y) 0.0 (0–1), 3 ND ND ND ND ND ND ND
a The Mann-Whitney U test was used to compare between-group distributions for unpaired data. , a P value of 0.05 compared with mock-infected and
WT-NTBF-infected mice; , a P value of 0.05 compared with rNTBF- and WT-NTBF-infected mice. ND, not determined.
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adherence. Although our data strongly suggest a central role
for BFT secretion in ETBF disease pathogenesis, our germfree
mouse studies using rETBF (bft-2) and rNTBF (bft-2 H352Y)
suggest that other virulence factors may drive the early
mortality associated with colitis observed in this murine
model (35, 39).
Our in vivo murine data confirm the relevance of prior in
vitro studies of the BFT mechanism of action to understanding
the pathogenesis of ETBF disease. In vitro studies indicated
that BFT binds to a putative intestinal epithelial cell receptor
stimulating signal transduction pathways, resulting in the fol-
lowing: (i) E-cadherin cleavage with reduced barrier function
in CEC monolayers (59), (ii) -catenin signaling with induction
of c-Myc expression and CEC proliferation (57), and (iii) ac-
tivation of NF-B with expression and secretion of IL-8 and
other cytokines (18, 42, 57, 58). The studies herein confirm for
the first time that E-cadherin cleavage occurs in vivo early in
ETBF-induced murine colitis. E-cadherin is important for in-
testinal barrier function (61), and chimeric mice expressing a
dominant negative N-cadherin in CECs lose intercellular E-
cadherin associations and develop colitis (13). Our preliminary
data (unpublished data) indicate that early ETBF colitis is also
associated with expression of the chemokine KC, the murine
IL-8 analog. Our data support the concept that diminished
barrier function is an early step in the development of colonic
inflammation as proposed for human IBD (16, 48). Herein, we
also demonstrate ETBF-induced CEC hyperplasia (Fig. 5a)
with increased Ki67 and cyclin D1 expression, the latter a
downstream target of -catenin signaling and c-Myc induction
known to be triggered by BFT (12, 49). While crypt hyperplasia
is common with experimental colitis, the colon histopathology
from mice colonized with ETBF for 16 months (Fig. 5b) re-
veals hyperplasia without gross CEC barrier disruption and
inflammation (compare Fig. 2a and 5b). More detailed studies
are needed to discern the mechanisms of ETBF-induced in-
flammation and hyperplasia and to determine if these are mo-
lecularly linked mucosal events. Lastly, our results did not
show direct activation of TLRs or immune cells by BFT con-
sistent with in vitro data, indicating that BFT specifically binds
only to epithelial cell lines that express E-cadherin and polar-
ize in vitro (60). Additional studies are necessary to define the
mechanisms by which ETBF and BFT activate the mucosal and
systemic immune system and to identify the specific BFT cell
receptor. Our data suggest that the BFT receptor is present
FIG. 5. ETBF chronic infection enhances epithelial hyperplasia. (a) H&E staining and anti-cyclin D1 immunohistochemistry of ceca from mice
persistently infected (for 1 month) with WT-NTBF and WT-ETBF (bft-2). Results for mock-infected mice are identical to those for WT-NTBF-
infected mice (data not shown). (b) H&E staining of ceca from mice persistently infected for 8 months [WT-NTBF and WT-ETBF (bft-2)] and
16 months [WT-NTBF and rETBF(bft-2)].
FIG. 6. ETBF induces colitis in germfree mice. Germfree 129S6/SvEv mice (4 to 10 months old) were inoculated with WT-ETBF (bft-2),
rETBF (bft-2), or rNTBF (bft-2 H352Y), and ceca were prepared for histology 3 days later. Bars, 100 m.
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throughout the intestine since BFT stimulated E-cadherin
cleavage in small intestinal and colonic tissues (Fig. 4a). Thus,
the colonic localization of WT-ETBF-induced disease likely
relates to the colonic environment and as-yet-uncharacterized
B. fragilis adherence factors.
The potent antibody response specific to WT-ETBF (bft-2)
was unexpected considering the short-term infection but likely
was facilitated by BFT-induced colitis with translocation of
luminal antigens and systemic immune activation as evidenced
by splenomegaly in ETBF-colonized mice. Although blood and
peripheral tissue cultures of WT-ETBF (bft-2)- and rETBF
(bft-2)-infected mice were negative (n 
 5), it is possible that
B. fragilis transiently invaded the periphery. The size and dif-
fuse appearance of the WT-NTBF and WT-ETBF (bft-2) an-
tigens detected by Western blot analysis (Fig. 3) suggest anti-
body reactivity to the unique and antigenically potent B. fragilis
polysaccharide capsules of the inoculated B. fragilis strains. In
contrast, murine BFT-specific antibodies were not detected de-
spite the known immunogenicity of BFT in rabbits and humans
(45). It is possible that Western blot analysis is too insensitive or
that only murine mucosal antibodies are produced.
Although WT-NTBF-colonized mice did not exhibit any co-
lonic inflammation, we detected weak antibody responses to
NTBF, indicating a systemic adaptive immune response to
NTBF, a finding consistent with a recent report of peripheral
CD4 T lymphocyte expansion in NTBF-colonized germfree
mice (26). Our results extend these prior observations, showing
initiation of adaptive immune responses to NTBF within 1
week of colonization, but differ from results of Konrad et al.
(20) who reported that the murine immune responses to en-
teric bacteria were tightly compartmentalized to the mucosa in
conventional mice. These differences suggest that the interac-
tion of B. fragilis with the host is complex and differs from other
common fecal flora.
Recently, Nakano et al. (31) reported that outbred germfree
NIH (Swiss Webster) mice housed under short-term germfree
conditions and infected with a human strain of WT-ETBF
developed only mild, nonlethal colitis. Potential reasons for the
experimental discrepancies include differences in susceptibility
to colitis by different mouse strains and different amounts of
BFT secretion among clinical strains of ETBF (4, 43, 53).
Nonetheless, our experiments indicate that monoinfection with
at least some WT-ETBF strains is sufficient to induce profound
colonic inflammation.
In small studies, ETBF colonization in humans has been asso-
ciated with active IBD (2, 36) and colorectal cancer (50). Reports
estimate that 4 to 30% of healthy individuals harbor ETBF
without obvious symptoms. We hypothesize that humans harbor-
ing ETBF or potentially similar as-yet-unidentified commensals
may be at risk for the deleterious consequences of persistent,
subclinical colonic inflammation such as IBD, oncogenic se-
quelae, and/or irritable bowel syndrome. Consistent with our hy-
pothesis, we previously reported that mice given subclinical doses
of DSS followed by ETBF colonization show exacerbated colitis
(37) and that in Bangladeshi patients with ETBF, persistent in-
testinal inflammation was present 3 weeks postinfection even if
ETBF was cleared with antibiotic therapy (45). To date, we have
not observed colonic neoplasms in mice persistently colonized
with WT-ETBF (bft-2) or rETBF (bft-2) at up to 16 months of
age. Well-designed clinical studies are necessary to determine the
long-term consequences of ETBF colonization.
In summary, we describe ETBF-induced colitis in colitis-resis-
tant antibiotic-treated SPF C57BL/6 mice that mirrors acute and
persistent infection observed in ETBF-infected individuals. Our
data indicate that BFT is necessary and sufficient to induce colitis
in both conventional and germfree mice. Studies to define the
immunopathogenesis of ETBF colitis are in progress. The future
translational challenge will be to identify if select members of the
intestinal flora such as ETBF are key to the pathogenesis of
colonic inflammatory conditions and their sequelae.
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